AYTU BioPharma, Inc. Common Stock (AYTU) is a publicly traded Healthcare sector company. As of May 21, 2026, AYTU trades at $2.20 with a market cap of $22.54M and a P/E ratio of -0.99. AYTU moved +0.00% today. Year to date, AYTU is -25.86%; over the trailing twelve months it is +5.91%. Its 52-week range spans $0.95 to $3.07. Analyst consensus is strong buy with an average price target of $9.33. Rallies surfaces AYTU's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Aytu BioPharma Q3 Revenue Climbs 18% to $4.7M on Exua Prescription Surge: Aytu BioPharma posted Q3 2026 revenue of $4.7 million, up 18% sequentially, driven by a 35% rise in Exua prescriptions. The net loss narrowed to $1.2 million as Exua’s improved product margins boosted overall profitability.
| Metric | Value |
|---|---|
| Price | $2.20 |
| Market Cap | $22.54M |
| P/E Ratio | -0.99 |
| EPS | $-2.16 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.07 |
| 52-Week Low | $0.95 |
| Volume | 25 |
| Avg Volume | 0 |
| Revenue (TTM) | $66.38M |
| Net Income | $-13.56M |
| Gross Margin | 69.04% |
3 analysts cover AYTU: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $9.33.